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Abstract 
Background 
New cases of oropharyngeal squamous cell carcinoma (OPSCC) are routinely tested for 
HPV. HPV in saliva can be detected with PCR, but its clinical applicability in the context 
of OPSCC remains unknown.  
 
Methods 
Forty-six consecutive patients diagnosed with OPSCC had pre-treatment saliva specimens 
collected. PCR for HPV on saliva was compared to p16 IHC and HPV DNA in-situ hybridisation 
(ISH) on surgical biopsies.  
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Results 
The sensitivity and specificity of saliva testing when compared to the reference test of p16 IHC 
and HPV DNA ISH was 72.2% and 90% and positive and negative predictive values were 96.3% 
and 47.4%. There were no adverse events. Time from last meal, smoking, alcohol drinking and 
physical exercise did not impact on results.  
 
Conclusions 
Saliva testing is a promising test to detect HPV in patients with OPSCC. A positive result could 
avoid the need for surgical biopsies, thereby reducing costs, patient morbidity, and expedite 
treatment.  
 
Introduction:  
Oropharyngeal squamous cell carcinoma (OPSCC) which affects the tonsils and tongue 
base is traditionally associated with excess alcohol consumption and smoking. Despite a 
reduction in smoking and alcohol consumption, the UK incidence of OPSCC doubled 
between 1990 and 2006 and then again between 2006 and 2010[1]. This increase is 
mirrored in many developed countries[2], with approximately 63,000 new cases of 
OPSCC reported annually [3]. The majority are now attributed to HPV infection 
(HPV+ve)[2]. A worldwide meta-analysis has shown that HPV associated OPSCC has 
increased from 40.5% before 2000 to 72.2% after 2005 [4]. HPV+ve OPSCC is set to 
overtake the incidence of HPV associated cervical cancer by 2020 [5] and is a major 
health epidemic in the western world [6]. 
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HPV detection is emerging as a biomarker for patients with OPSCC. The presence of HPV in 
OPSCC can predict prognosis and determine suitability for entry into de-escalation clinical trials 
aimed at improving long-term quality of life[7,8]. In fact, HPV+ve and HPV-ve OPSCC are staged 
separately in the latest edition of the AJCC cancer staging manual[9]. Whilst current treatments 
are not based on HPV status (outside of clinical trials), the new staging system is likely to have 
an impact.  
 
HPV testing using p16 immunohistochemistry (IHC) on surgical or core biopsies is considered 
the standard of care for patients with OPSCC, and is recommended in all patients by the UK 
National Institute for Health and Care Excellence (NICE)[10]. p16 IHC is also the standard of 
care utilised by the AJCC in determining the presence of HPV in patients with OPSCC[9].  Other 
techniques for HPV testing including the sensitivity and specificity of these tests are described 
in Table 1.  
 
HPV testing for OPSCC is typically performed on surgically obtained biopsies performed 
under general anaesthesia or on core biopsies of suspected lymph node metastasis 
obtained under ultrasound guidance. These investigations have associated costs and 
risks including pain, bleeding, infection, dental injury, oesophageal perforation and 
rarely airway compromise. The procedures can result in delays to the patient pathway 
particularly when a diagnosis of squamous cell carcinoma is first made with fine needle 
aspiration cytology (FNAC). In these cases a supplementary surgical or core biopsy is 
needed from the primary site or nodal metastasis to confirm p16 status. With existing 
pressures on cancer diagnostic services[11], the process from initial presentation to 
establishing the HPV status on a biopsy of a patient with OPSCC may take weeks.  
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HPV is detectable in the saliva of patients with OPSCC using PCR. This non-invasive, 
relatively inexpensive test, without side effects and taken at the point of first patient 
contact could allow for the HPV status of patients to be established much earlier. 
Salivary HPV testing has the potential to mitigate the need for invasive biopsies 
performed solely for the purpose of HPV detection, and could form a routine part of 
screening and risk stratification in patients suspected of OPSCC. To our knowledge, 
there is no prospective diagnostic accuracy study directly comparing the efficacy of oral 
rinse testing to the clinically accepted standards of p16 IHC and DNA ISH in patients 
with OPSCC.   
 
Aims:  
The aim of this study was to determine the sensitivity and specificity of oral rinse (OR) testing 
for HPV in patients with OPSCC.  
 
Materials and Methods: 
A prospective diagnostic accuracy study estimating the sensitivity and specificity of oral 
rinse testing using PCR for HPV to p16 IHC and DNA ISH in patients with OPSCC was 
conducted.  The study flow diagram is shown in Figure 1.   Both QUADAS-2 [12] and 
STARD criteria [13] were adopted. Ethical approval was sought in collaboration with 
the Oxford Radcliffe Biobank (Ref No. 09/H0606/5+5).  
Between September 2015 and June 2016, sixty-three patients were referred to the Oxford 
University Hospitals (OUH) Head and Neck Cancer Service with suspected OPSCC. Consecutive 
adult patients (aged >18) with mental capacity and suspected OPSCC were invited to 
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participate. All patients met initial inclusion criteria, one patient declined consent. Oral rinse 
(OR) specimens and demographic data were collected from the 62 consenting patients prior to 
commencing diagnostic assessment and cancer treatment. 47 patients were subsequently 
confirmed to have a diagnosis of OPSCC and were included in this study. 
 
A standard operating procedure was developed whereby patients were asked to ‘gargle’ 10mls 
of sterile sodium chloride solution for 20-30 seconds. This was collected in a sterile universal 
container and stored within 2 hours of collection at -80°C. OPSCC tumour biopsies were 
performed under general anaesthesia and formalin fixed, paraffin embedded tissue was 
assessed for routine diagnostic histopathology. Immunostaining for p16 was performed on all 
cases and confirmatory HPV DNA ISH on twenty-nine. HPV DNA ISH was performed when felt to 
be of clinical value, this was at the discretion of the reporting Consultant Head and Neck 
pathologist.  
 
p16 IHC was considered positive when >70% of cells showed strong nuclear and/or 
cytoplasmic staining [10].  HPV DNA ISH was carried out using the Ventana INFORM HPV III 
Family 16 Probe (B) (MDCI Ltd, West Sussex UK). The probe cocktail has demonstrated affinity 
to the following genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66. 
 
The index test (Linear Array HPV Genotyping Test Kit – Roche ©) was performed by the 
OUH Molecular Diagnostics Department in accordance with the manufacturers 
instructions on all 47 samples. HPV DNA was extracted from each OR sample by lysing 
cells in denaturing conditions at elevated temperatures.  PCR amplification for 37 
different HPV subtypes was performed using the provided ‘master mix’. Hybridization 
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was used to label oligonucleotide probes before using a Streptavidin-Horseradish 
peroxidase conjugate to identify HPV status and sub-type using the Linear Array HPV 
Genotyping Test Reference Guide. Suitable controls were used at each stage of the 
process. There was one OR test failure meaning that 46 of 47 eligible patients were 
included in the final analysis. Both reference and index tests were conducted by 
qualified technicians blinded to the clinical presentation and results.  
 
When the results of p16 IHC and DNA ISH were combined to determine HPV status a sample 
was considered positive if it was either p16 IHC positive with no HPV DNA ISH test, p16 IHC 
positive and HPV DNA ISH positive or p16 IHC negative and DNA ISH positive. A sample was 
considered HPV negative if it was p16 IHC negative with no HPV DNA ISH test, p16 IHC negative 
and HPV DNA ISH negative or p16 IHC positive and DNA ISH negative.  
 
Statistical Analysis 
A power calculation was conducted using Stata 13 (StataCorp LP) software to determine a 
sample size of 45 for 80% power to determine results with a standard error of 5% and 10% 
confidence intervals. All statistical analyses were pre-determined and performed using Prism 6 
for Mac OS X (© 1994-2015 GraphPad Software, Inc). The demographic differences in the 
patient population based on p16 IHC and ‘true vs false’ OR results were analysed using a 
Fisher’s exact test when categorical values were less than 5 and a Chi2 test when they were 
greater than 5 or when there were more than 2 categories. A result was considered significant 
when p was <0.05. Sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) and their 95% confidence intervals were calculated.  
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Results 
The mean age of participants was 58.8 years (range; 37-80) (see Table 2). There were 35 males 
(76.1%) and 11 females (23.9%); all patients were of Caucasian descent. The mean alcohol 
consumption was 19.8 units per week; there were 34 (73.9%) current or ex tobacco smokers 
with an average 23.2 pack year (range; 1-50) smoking history. The majority of patients 
presented with T1/2 tumours (71.7%) with advanced local metastases in 78.3% (N2/3). One 
patient (2.2%) had distant metastases. Five patients had Stage 1, 28 Stage 2 and 13 Stage 3 
disease (ICON-S). 
 
There were 34 (73.9%) p16 positive (+ve) and 12 (26.1%) p16 negative (-ve) samples. There 
were no statistically significant differences between the two groups in terms of age, sex, co-
morbidities, alcohol consumption, smoking status, tumour size or distant metastases. Patients 
with p16+ve OPSCC presented with a higher N stage than those that were p16-ve  (85.3% vs 
58.3% p=0.05).  
 
Disease Prevalence, Sensitivities, Specificities and Predictive Values for HPV  
The patient specimens were categorised into 3 groups for analysis: those that had p16 IHC and 
OR testing (n=46), those with DNA ISH and OR testing (n=29) and those that had p16 IHC with 
or without DNA ISH and OR testing (n=46). The patients and test results for each group are 
summarised in Figure 2 and Table 3.  
 
Using the previously described method for combined p16 IHC and DNA ISH as the reference test 
there were 36 HPV positive (78.3%) and 10 HPV negative (21.7%) samples. Of the 36 HPV 
positive samples 26 were positive and 10 negative on OR testing.  Out of the 10 HPV negative 
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samples 1 was positive and 9 negative on OR testing. The prevalence of HPV was 78.3% (63.6%-
89.1% 95% CI). The sensitivity and specificity of OR testing when compared to the reference 
test of p16 IHC with and without HPV DNA ISH was 72.2% (54.8%-85.8% 95% CI) and 90% 
(55.5%-99.8% 95% CI) and PPV and NPV were 96.3% (81.0%-99.9% 95% CI) and 47.4% 
(24.5%-71.1% 95% CI). 
 
Identification of HPV Sub-types 
Oral rinse testing using the Linear Array HPV Genotyping Test Kit (Roche ©) allows 
identification of up to 37 different HPV subtypes. Twenty-seven out of 46 ‘oral rinse’ tests were 
positive for HPV (see Figure 3). There was 1 false positive result that suggested the presence of 
HPV 16 (p16 IHC and HPV DNA ISH negative). HPV 16 alone was detected in 21 samples 
(77.8%); HPV 18 alone in 1 sample (3.7%), whilst the remaining 5 samples (18.5%) all 
contained HPV 16 alongside other HPV subtypes. The combinations detected were HPV 
16/33/35/52/58, HPV 16/31/35, HPV 16/53, HPV 16/84 and HPV 16/55/73/84.  
 
Evaluating Potential Confounding Factors 
To evaluate potential patient demographic, tumour or environmental factors that may have 
resulted in a false test result additional patient specific information was collected including time 
of last alcoholic drink, smoke, meal and exercise (see Table 4). Using the reference standard of 
combined p16 IHC and HPV DNA ISH as previously described there were 35 patients (76.1%) 
with a true positive or negative result and 11 (23.9%) with a false positive or negative result. 
There was no statistically significant difference between the two groups in terms of age, co-
morbidities, T/N/M stage, last meal/smoke/alcohol or exercise.  
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Adequacy of Samples and Adverse Events 
One (2.1%) of 47 oral rinse tests failed to provide a result despite confirming adequacy of DNA 
and repetition; the cause for this remains unclear. Whilst some patients reported that the taste 
of sodium chloride was unpleasant and some needed to repeat the test due to spillage, there 
were no adverse events associated with oral rinse testing.   
 
Discussion 
Our study has demonstrated that OR testing using PCR to detect HPV in patients with OPSCC has 
sensitivity, specificity, positive and negative predictive values of 72.2%, 90%, 96.3% and 47.4% 
respectively. Whilst the NPV is low making interpreting a negative result unreliable, with one 
sample failure and no adverse events reported this study demonstrates that PCR on oral rinse 
specimens is a viable method for determining HPV in OPSCC. Smoking, alcohol consumption, 
last meal and exercise do not appear to affect the accuracy of OR testing meaning that specific 
pre-test preparation is not required.  
 
Testing for HPV in OPSCC is increasingly important as HPV status can provide important 
diagnostic and prognostic information. Testing needs to be sensitive and specific, reproducible 
and validated. There is considerable debate as to the optimum test for HPV[14].  The commonly 
described techniques of p16 IHC, HPV DNA ISH and PCR on tumour tissue have associated 
advantages and disadvantages[15]. HPV DNA ISH is able to demonstrate HPV integration within 
tumour cells, but as it detects DNA and not mRNA it also does not confirm transcriptional 
activity[15].  p16 IHC, although not 100% specific is emerging as a prognostic marker for OPSCC 
in its own right [16,17]. It is considered a surrogate marker of HPV transcriptional activity[15]. 
There are associated limitations, Wasylyk et al (2013) [18] reported p16 IHC alone confirmed a 
significant number of false positives for HPV when compared to p16 IHC supplemented by 
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either PCR or DNA/RNA ISH. PCR for HPV is highly sensitive; whilst this has obvious advantages 
it is not always possible to tell if the DNA detected relates to the tumour cells or surrounding 
normal tissue[15].  
 
OR testing offers an alternative to conventional HPV testing in OPSCC with potential benefits of 
reduced patient morbidity, shorter time to diagnosis and reduced cost. It is also limited by the 
highly sensitive nature of PCR, whereby detected HPV DNA might not relate to tumour tissue, 
and instead represent a bystander infection.   
 
The sensitivity of salivary testing however has been questioned with some authors 
reporting an inability to detect HPV from OR specimens in patients with known HPV+ve 
OPSCC [19]. Zhao et al [20] detected HPV in 50% (21 of 42 specimens) of salivary 
samples from patients with HPV+ve OPSCC using PCR. Whilst Wang et al[21] found that 
saliva was inferior to plasma when testing for HPV in patients with OPSCC. They 
detected HPV in 40% of their salivary specimens and 86% of their plasma specimens. 
Our results contradict these findings; whilst plasma testing for HPV was not performed 
we were able to detect HPV in the saliva of HPV+ve cases in 72.2% of cases. This could 
relate to the way samples were collected, processed and stored in the studies.  
 
Although the results of our study, which to our knowledge is the first of its kind, are promising, 
it is important to consider the results of PCR testing for HPV using other non-invasive biopsies. 
Channir et al [22] recently utilised PCR on fine needle aspirates (FNAs) of patients with OPSCC 
reporting 94.7% sensitivity and 100% specificity whilst Brogile et al [23] used PCR on 
oropharyngeal brush cytology specimens from patients with OPSCC reporting sensitivity and 
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specificity values of 83% and 94%.  Although these results seem superior to OR testing, FNA 
assessment and brush cytology analysis have limitations. Specifically FNAs are limited by the 
quality of the sample obtained which may be operator dependant [24] whilst inadequate 
sampling from oropharyngeal brush cytology is high (45.7%) [25]. Both tests require further 
clinical validation.    
 
Unlike other diagnostic accuracy studies utilising non-invasive biopsies to determine HPV 
status in OPSCC this study was carried out prospectively using QUADAS-2 and STARD criteria to 
limit bias and mirror clinical practise. Patients were included consecutively, analyses 
predetermined and participants closely reflected those seen in clinical practise e.g. HPV 
prevalence >70%, no involuntary exclusions.  Both reference and OR tests were performed by 
qualified technicians blinded to the study objectives and other test results to limit bias.   
 
This study was limited by the lack of E6/7mRNA testing considered the research ‘gold standard’ 
for HPV detection in OPSCC [26]. Whilst the clinical standards of p16 IHC and DNA ISH were 
utilised as reference tests all included samples did not have HPV DNA ISH performed. This could 
have introduced bias in the results and underestimated the specificity and negative predictive 
value of OR testing. Nonetheless, the reference test utilised represented clinically acceptable 
standards for HPV detection in OPSCC. Separate analyses were performed for p16 IHC alone and 
p16 IHC supplemented by DNA ISH when clinically indicated.  
 
Given the negative impact of delayed diagnosis and treatment, OR testing could allow for 
immediate HPV testing at the primary clinical presentation even before specialist consultation. 
The relatively high specificity and PPV and low NPV mean that a positive OR test could be relied 
upon whilst a negative test would require additional conventional testing. General practitioners 
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could take samples from patients at the time of specialist referral so that HPV status could be 
available at the first specialist assessment. Patients presenting with an oropharyngeal lesion 
and neck nodes (as in most cases of OPSCC) could then have a core biopsy performed at the 
specialist consultation followed by cross-sectional imaging for staging. These results could 
provide the treating clinician with a tissue diagnosis, HPV status (if OR positive) and 
radiological stage. In selected cases, for example when a patient is deemed medically unfit for 
surgery, this could be sufficient to plan treatment and avoid the risks and time associated with 
surgical biopsies.  
 
There is a need for large prospective studies that look not only at the diagnostic accuracy of HPV 
detection in OPSCC but also at recurrence and the role of HPV testing in surveillance. It may be 
that OR testing alone may not be sufficient and require combination with other non-invasive 
tests. Ahn et al[27] recently tested both saliva and serum to detect HPV in recurrent OPSCC with 
>90% specificity and 69.5% sensitivity. Future studies should compare all non-invasive 
diagnostic materials for HPV including brush cytology, FNA and serum plasma to both clinical 
and research standards for HPV detection e.g. DNA ISH, RNA ISH, p16IHC and HPV DNA PCR.    
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Table1:  Sensitivity and specificity of clinically available tests for HPV in OPSCC (Schache 
et al 2011) [13]. 
Test Sensitivity Specificity 
P16 IHC 94-100% 79-82% 
PCR 97% 87% 
DNA ISH 89% 89% 
 
 
 
 
 
Table 2: Patient Demographics and Tumour Characteristics by p16 Status 
  Tumour HPV Status, No.(%)  
 
 
 
Sex 
Total 
Patients, 
No.(%) 
N=46 
p16 +ve,No.(%) 
(n=34) 
p16 -ve, 
No.(%)(n=12) 
P- Value 
 
Male 35 (76.1) 25 (73.5) 10 (83.3) 0.70 
Female 11(23.9) 9 (26.5) 2 (16.7)  
Age, (years)     
>60 18 (39.1) 12 (35.3) 6 (50) 0.37 
<60 28 (60.9) 22 (64.7) 6 (50)  
ASA grade     
1/2 42(91.3) 32(94.1) 10(83.3) 0.28 
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3/4/5 4 (8.7) 2(5.9) 2(16.7)  
Ethnicity     
Caucasian 46 (100) 34 (100) 12 (100) n/a 
Drinking Status     
Nil 6 (13) 5 (14.7) 1 (8.3) 0.12 
1-21 units/week 29 (63) 22 (64.7) 7 (58.3)  
21-40 
units/week 
7 (15.2) 6 (17.6) 1 (8.3)  
>40 units/week 4 (8.7) 1 (2.9) 3 (25)  
Smoking status     
Never 12 (26.1) 10 (29.4) 2 (16.7) 0.44 
Ex-smoker 21 (45.7) 16 (47.1) 5 (41.7)  
Current 13 (28.3) 8 (23.5) 5 (41.7)  
T Classification     
T1/2 33 (71.7) 25 (73.5) 8 (66.7) 0.71 
T3/4 13 (28.3) 9 (26.5) 4 (33.3)  
N Classification     
N0/1 10 (21.7) 5 (14.7) 5 (41.7) 0.05 
N2/3 36 (78.3) 29 (85.3) 7 (58.3)  
M classification     
M0 45 (97.8) 33 (97.1) 12 (100) 1.00 
M1 1 (2.2) 1 (2.9) 0 (0)  
 
Abbreviations: n/a, not applicable; ASA, American Society of Anaesthesiologists Performance 
Status.  
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Table 3: Sensitivity, Specificity, Disease Prevalence and Predictive Values of ‘oral rinse 
testing’ against clinical standard tests of  (A) p16 IHC (B) HPV DNA ISH and (C) Combined 
p16 IHC/DNA ISH 
 
 
 
Abbreviations: CI, confidence interval; HPV, human papilloma virus; DNA ISH, DNA in situ 
hybridisation; p16 IHC, p16 immunohistochemistry; PPV, positive predictive value; NPV, 
negative predictive value.   
 
 
 
 
 
 
 
 
 
 
  HPV 
Prevalence 
(%) 
Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
A 
‘oral rinse' vs p16 IHC,  
% (95% CI) 
73.9(58.9-85.7) 73.5(55.6-87.1) 83.3(51.6-97.9) 92.6(75.7-99.1) 52.6(28.9-75.6) 
B 
‘oral rinse' vs HPV DNA 
ISH, 
 % (95% CI) 
72.4(52.8-87.3) 66.7(43-85.4) 87.5(47.4-99.7) 93.3(68.1-99.8) 50.0(23.0-77.0) 
C 
‘oral rinse’ vs p16 IHC 
+/- HPV DNA ISH,  
% (95% CI) 
78.3(63.6-89.1) 72.2(54.8-85.8) 90(55.5-99.8) 96.3(81.0-99.9) 47.4(24.5-71.1) 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 4: Comparing patient differences between ‘True’ and ‘False’ results 
 
  Oral Rinse Test Result  
 Total 
Patients, 
No.(%) 
N=46 
True +ve/-ve, 
No.(%) 
(n=35) 
False +ve/-ve, 
No.(%) 
(n=11) 
P- Value 
 
Age, (years)     
>60 18(39.1) 16(45.7) 2(18.2) 0.16 
<60 28(60.9) 19(54.3) 9(81.8)  
ASA     
1/2 42(91.3) 31(88.6) 11(100) 0.56 
3/4/5 4(8.7) 4(11.4) 0(0)  
T Classification     
T1/2 33(71.7) 24(68.6) 9(81.8) 0.47 
T3/4 13(28.3) 11(31.4) 2(18.2)  
N Classification     
N0/1 10(21.7) 8(22.9) 2(18.2) 0.99 
N2/3 36(78.3) 27(77.1) 9(81.8)  
M classification     
M0 45(97.8) 34(97.1) 11(100) 0.99 
M1 1(2.2) 1(2.9) 0(0)  
Last Alcoholic Drink    
Never 16(34.8) 12(34.3) 4(36.4) 0.82 
< 6 hours 1(2.2) 1(2.9) 0(0)  
6-24 hours 20(43.5) 16(45.7) 4(36.4)  
> 24 hours 9(19.6) 6(17.1) 3(27.3)  
Last Smoke     
Never 34(73.9) 26(74.3) 8(72.7) 0.40 
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Abbreviations: n/a, not applicable; ASA, American Society of Anaesthesiologists Performance 
Status.  
 
 
< 6 hours 7(15.2) 4(11.4) 3(27.3)  
6-24 hours 2(4.3) 2(5.7) 0(0)  
> 24 hours 3(6.5) 3(8.6) 0(0)  
Last Meal     
< 2 hours 7(15.2) 4(11.4) 3(27.3) 0.30 
2-6 hours 25(54.3) 21(60) 4(36.4)  
> 6 hours 14(30.4) 10(28.6) 4(36.4)  
Last Exercise     
< 6 hours 4(8.7) 4(11.4) 0(0) 0.44 
6-24 hours 10(21.7) 8(22.9) 2(18.2)  
> 24 hours 32(69.6) 23(65.7) 9(81.8)  
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